Multidrug Resistence Prevalence in COVID Area
Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, is often complicated by severe acute respiratory syndrome. The new coronavirus outbreak started in China in December 2019 and rapidly spread around the world. The high diffusibility of the virus was the reason for the outbreak of the pandemi...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/11/7/601 |
| _version_ | 1827689007205580800 |
|---|---|
| author | Caterina Aurilio Pasquale Sansone Antonella Paladini Manlio Barbarisi Francesco Coppolino Vincenzo Pota Maria Caterina Pace |
| author_facet | Caterina Aurilio Pasquale Sansone Antonella Paladini Manlio Barbarisi Francesco Coppolino Vincenzo Pota Maria Caterina Pace |
| author_sort | Caterina Aurilio |
| collection | DOAJ |
| description | Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, is often complicated by severe acute respiratory syndrome. The new coronavirus outbreak started in China in December 2019 and rapidly spread around the world. The high diffusibility of the virus was the reason for the outbreak of the pandemic viral disease, reaching more than 100 million infected people globally by the first three months of 2021. In the various treatments used up to now, the use of antimicrobial drugs for the management, especially of bacterial co-infections, is very frequent in patients admitted to intensive care. In addition, critically ill patients with SARS-CoV-2 infection are subjected to prolonged mechanical ventilation and other therapeutic procedures often responsible for developing hospital co-infections due to multidrug-resistant bacteria. Co-infections contribute to the increase in the morbidity–mortality of viral respiratory infections. We performed this study to review the recent articles published on the antibiotic bacterial resistance and viruses to predict risk factors of coronavirus disease 2019 and to assess the multidrug resistance in patients hospitalized in the COVID-19 area. |
| first_indexed | 2024-03-10T10:08:33Z |
| format | Article |
| id | doaj.art-75694fd92a68462fbaaca3ff8374f3a5 |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-10T10:08:33Z |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-75694fd92a68462fbaaca3ff8374f3a52023-11-22T01:20:02ZengMDPI AGLife2075-17292021-06-0111760110.3390/life11070601Multidrug Resistence Prevalence in COVID AreaCaterina Aurilio0Pasquale Sansone1Antonella Paladini2Manlio Barbarisi3Francesco Coppolino4Vincenzo Pota5Maria Caterina Pace6Department of Women, Child, General and Specialistic Surgery, University of Campania “L. Vanvitelli”, 80138 Napoli, ItalyDepartment of Women, Child, General and Specialistic Surgery, University of Campania “L. Vanvitelli”, 80138 Napoli, ItalyDepartment of MESVA, University of L’Aquila, 67100 L’Aquila, ItalyDepartment of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania “Luigi Vanvitelli”, 80138 Naples, ItalyDepartment of Women, Child, General and Specialistic Surgery, University of Campania “L. Vanvitelli”, 80138 Napoli, ItalyDepartment of Women, Child, General and Specialistic Surgery, University of Campania “L. Vanvitelli”, 80138 Napoli, ItalyDepartment of Women, Child, General and Specialistic Surgery, University of Campania “L. Vanvitelli”, 80138 Napoli, ItalyCoronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, is often complicated by severe acute respiratory syndrome. The new coronavirus outbreak started in China in December 2019 and rapidly spread around the world. The high diffusibility of the virus was the reason for the outbreak of the pandemic viral disease, reaching more than 100 million infected people globally by the first three months of 2021. In the various treatments used up to now, the use of antimicrobial drugs for the management, especially of bacterial co-infections, is very frequent in patients admitted to intensive care. In addition, critically ill patients with SARS-CoV-2 infection are subjected to prolonged mechanical ventilation and other therapeutic procedures often responsible for developing hospital co-infections due to multidrug-resistant bacteria. Co-infections contribute to the increase in the morbidity–mortality of viral respiratory infections. We performed this study to review the recent articles published on the antibiotic bacterial resistance and viruses to predict risk factors of coronavirus disease 2019 and to assess the multidrug resistance in patients hospitalized in the COVID-19 area.https://www.mdpi.com/2075-1729/11/7/601COVID-19multidrug-resistantrisk factorsclinical characteristics |
| spellingShingle | Caterina Aurilio Pasquale Sansone Antonella Paladini Manlio Barbarisi Francesco Coppolino Vincenzo Pota Maria Caterina Pace Multidrug Resistence Prevalence in COVID Area Life COVID-19 multidrug-resistant risk factors clinical characteristics |
| title | Multidrug Resistence Prevalence in COVID Area |
| title_full | Multidrug Resistence Prevalence in COVID Area |
| title_fullStr | Multidrug Resistence Prevalence in COVID Area |
| title_full_unstemmed | Multidrug Resistence Prevalence in COVID Area |
| title_short | Multidrug Resistence Prevalence in COVID Area |
| title_sort | multidrug resistence prevalence in covid area |
| topic | COVID-19 multidrug-resistant risk factors clinical characteristics |
| url | https://www.mdpi.com/2075-1729/11/7/601 |
| work_keys_str_mv | AT caterinaaurilio multidrugresistenceprevalenceincovidarea AT pasqualesansone multidrugresistenceprevalenceincovidarea AT antonellapaladini multidrugresistenceprevalenceincovidarea AT manliobarbarisi multidrugresistenceprevalenceincovidarea AT francescocoppolino multidrugresistenceprevalenceincovidarea AT vincenzopota multidrugresistenceprevalenceincovidarea AT mariacaterinapace multidrugresistenceprevalenceincovidarea |